John Borgman
About John Borgman
John Borgman serves as the Director of SME Biopharma Proposition at Thomson Reuters and has held the position of Director of Commercial Competitive Intelligence at Clarivate since 2016. He possesses an MBA from William Howard Taft University and a B.A. from the University of California, Santa Cruz.
Current Role at Thomson Reuters
John Borgman serves as the Director of SME Biopharma Proposition at Thomson Reuters. He has held this position since 2015, contributing to the company's focus on the biopharmaceutical sector. In this role, he oversees BioWorld, which is recognized as an award-winning daily news source that provides insights into the biopharmaceutical and medical technology industries. His leadership in this area supports the dissemination of critical information to stakeholders in the sector.
Work at Clarivate
Borgman has been the Director of Commercial Competitive Intelligence at Clarivate since 2016. In this capacity, he directs predictive analytics and artificial intelligence projects within the information technology sector. His role involves leading the development of Cortellis Competitive Intelligence, a platform that offers comprehensive drug pipeline and commercial intelligence. This position underscores his expertise in competitive analysis and market intelligence.
Educational Background
John Borgman studied at William Howard Taft University, where he earned a Master of Business Administration (MBA) with a focus on Small Business. He also attended the University of California, Santa Cruz, where he completed a Bachelor of Arts degree in an Independent Major that combined Business and Communications. Additionally, he has educational roots at The Governor's Academy, which contributed to his foundational knowledge.
Previous Experience at Thomson Reuters
Before his current role at Thomson Reuters, John Borgman worked as the Director of IPD Product from 2013 to 2015. During this two-year tenure, he was responsible for overseeing product development initiatives within the company. His experience in this position laid the groundwork for his subsequent leadership role in the biopharma proposition.